title: Complexed prostate-specific antigen for the detection of prostate cancer.
abstract: BACKGROUND
  The description of a new method for the measurement of complexed prostate-specific antigen (cPSA) offers a new approach to the diagnosis of prostate cancer.
  
  
  METHODS
  We measured PSA (Hybritech and Bayer), free PSA (Hybritech) and complexed PSA (Bayer) in 72 patients with prostate cancer and 128 with benign prostate hyperplasia.
  
  
  CONCLUSIONS
  We found an increase of sensitivity using 25 and 7 ng/mL as cut-offs for cPSA in relation to total PSA using as cut-offs 4 and 10 ng/mL (96 and 36% vs. 92 and 35.5%). Similar differences were found for specificity (78% and 31% for cPSA vs. 73% and 29% for total PSA). Therefore, we defined a gray zone for patients with cPSA between 2.5 and 7 ng/mL for which the measurement of the free/complexed PSA ratio saves an important number of negative biopsies maintaining a higher sensitivity.
authors.affiliation: Department of Clinical Biochemistry (CDB), Hospital Clinic, Barcelona, Catalonia, Spain. xfilella@clinic.ub.es
authors.forename: Xavier
authors.initials: X
authors.lastname: Filella
authors.forename: David
authors.initials: D
authors.lastname: Truan
authors.forename: Joan
authors.initials: J
authors.lastname: Alcover
authors.forename: Rafael
authors.initials: R
authors.lastname: Gutierrez
authors.forename: Rafael
authors.initials: R
authors.lastname: Molina
authors.forename: Francisca
authors.initials: F
authors.lastname: Coca
authors.forename: Antonio M
authors.initials: AM
authors.lastname: Ballesta
mesh_terms: D000368:Aged; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis; D012372:ROC Curve; D011933:Reagent Kits, Diagnostic
chemical_list: D011933:Reagent Kits, Diagnostic; D017430:Prostate-Specific Antigen